On December 19, 2017 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco, California (Press release, Myriad Genetics, DEC 19, 2017, View Source [SID1234522709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.

On December 19, 2017 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the 36th Annual JP Morgan Health Care Conference on Monday, Jan. 8, at the Westin St. Francis in San Francisco. Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p.m. (Eastern Time) (Press release, Johnson & Johnson, DEC 19, 2017, View Source [SID1234522708]). A subsequent Question & Answer session is scheduled for 3:00 p.m. (Pacific Time)/6:00 p.m. (Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast for both events will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A recording of the webcasts and podcasts will be available approximately two hours after each event.

On December 19, 2017 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd, to review fourth-quarter results (Press release, Johnson & Johnson, DEC 19, 2017, View Source [SID1234522707]). Alex Gorsky, Chairman and Chief Executive Officer; Dominic Caruso, Executive Vice President, Chief Financial Officer and Joseph J. Wolk, Vice President, Investor Relations, will host the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast is accessible at Johnson & Johnson’s website: www.investor.jnj.com. A webcast will be available approximately three hours after the conference call concludes.
By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on January 31, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13674606.
Presentation materials will be available on www.investor.jnj.com.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

On December 19, 2017 AbbVie (NYSE: ABBV) reported that it will participate in the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 4, 2018 (Press release, AbbVie, DEC 19, 2017, View Source [SID1234522701]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On December 19, 2017 Seattle Genetics, Inc. (NASDAQ:SGEN) reported that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 10:30 a.m. Pacific Time (Press release, Seattle Genetics, DEC 19, 2017, View Source;p=RssLanding&cat=news&id=2323321 [SID1234522700]). Both the presentation and question and answer session that follows at 11:00 a.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!